16,713 Shares in Accolade, Inc. (NASDAQ:ACCD) Purchased by Rpo LLC

Rpo LLC purchased a new stake in Accolade, Inc. (NASDAQ:ACCD) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 16,713 shares of the company’s stock, valued at approximately $57,000.

Several other large investors have also recently added to or reduced their stakes in ACCD. Fairman Group LLC raised its stake in shares of Accolade by 58.5% in the fourth quarter. Fairman Group LLC now owns 1,802,399 shares of the company’s stock valued at $6,164,000 after acquiring an additional 665,112 shares during the last quarter. Geode Capital Management LLC boosted its stake in Accolade by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,782,038 shares of the company’s stock worth $6,862,000 after purchasing an additional 83,556 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Accolade by 84.1% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 634,470 shares of the company’s stock worth $2,170,000 after purchasing an additional 289,747 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Accolade in the third quarter valued at $2,378,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Accolade by 7.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 611,731 shares of the company’s stock valued at $2,092,000 after buying an additional 42,530 shares during the last quarter. 84.99% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on ACCD shares. Stifel Nicolaus reissued a “hold” rating and set a $7.03 price objective (down previously from $8.00) on shares of Accolade in a report on Thursday, January 9th. Piper Sandler lowered shares of Accolade from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Morgan Stanley reduced their price objective on Accolade from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Leerink Partners restated a “market perform” rating on shares of Accolade in a research report on Wednesday, January 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Accolade in a report on Wednesday, January 8th. Thirteen investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $6.51.

Accolade Stock Performance

Shares of NASDAQ:ACCD opened at $6.99 on Thursday. The company has a market capitalization of $573.13 million, a price-to-earnings ratio of -3.11 and a beta of 2.18. The firm’s 50 day simple moving average is $6.94 and its 200 day simple moving average is $5.02. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.63 and a quick ratio of 2.63. Accolade, Inc. has a fifty-two week low of $3.08 and a fifty-two week high of $9.67.

Accolade (NASDAQ:ACCD) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. As a group, sell-side analysts forecast that Accolade, Inc. will post -1.2 earnings per share for the current year.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.